Prior to laboratory analyses of the prospectively acquired patient biopsy specimens, we evaluated HER3 gene alteration (DNA mutations) in breast cancer patients, using the publicly available bioinformatic database, www.cbioportal.com. This evidence concerns the gene ERBB3 and breast cancer.